Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 07-Oct-24 5:47 PM View:  | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 03-Oct-24 | Planned Option Sale | 5,598 | $1.96 | $10,972.10 | (10%) 55.96K to 50.37K | |
| 07-Oct-24 5:48 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 03-Oct-24 | Planned Option Sale | 5,598 | $1.96 | $10,972.10 | (8%) 69.31K to 63.72K | |
| 07-Oct-24 5:46 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 03-Oct-24 | Planned Option Sale | 5,598 | $1.96 | $10,972.10 | (2%) 241.24K to 235.64K | |
| 07-Oct-24 5:47 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 03-Oct-24 | Planned Option Sale | 3,361 | $1.96 | $6,587.56 | (7%) 51.12K to 47.76K | |
| 07-Oct-24 5:48 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 03-Oct-24 | Planned Option Sale | 5,598 | $1.96 | $10,972.10 | (6%) 100.42K to 94.82K | |
| 07-Oct-24 5:47 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-24 | Planned Option Sale | 4,855 | $2.00 | $9,710.00 | (9%) 55.97K to 51.12K | |
| 07-Oct-24 5:48 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-24 | Planned Option Sale | 8,089 | $2.00 | $16,178.00 | (7%) 108.51K to 100.42K | |
| 07-Oct-24 5:47 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-24 | Planned Option Sale | 8,089 | $2.00 | $16,178.00 | (13%) 64.05K to 55.96K | |
| 07-Oct-24 5:48 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-24 | Planned Option Sale | 8,089 | $2.00 | $16,178.00 | (10%) 77.4K to 69.31K | |
| 07-Oct-24 5:46 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-24 | Planned Option Sale | 8,089 | $2.00 | $16,178.00 | (3%) 249.33K to 241.24K | |
| 07-Oct-24 5:48 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 01-Oct-24 | Option Exercise | 50,000 | -- | -- | 85% 58.51K to 108.51K | |
| 07-Oct-24 5:47 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 01-Oct-24 | Option Exercise | 50,000 | -- | -- | 356% 14.05K to 64.05K | |
| 07-Oct-24 5:48 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 01-Oct-24 | Option Exercise | 50,000 | -- | -- | 182% 27.4K to 77.4K | |
| 07-Oct-24 5:46 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 01-Oct-24 | Option Exercise | 50,000 | -- | -- | 25% 199.33K to 249.33K | |
| 07-Oct-24 5:47 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 01-Oct-24 | Option Exercise | 30,000 | -- | -- | 116% 25.97K to 55.97K | |
| 13-Sep-24 5:08 PM View: | Huber Martin H. Jr. President, CEO Director | Mersana Therapeutics, Inc. (MRSN) | 12-Sep-24 | Planned Option Sale | 50,423 | $1.76 | $88,744.50 | (30%) 166.75K to 116.33K | |
| 13-Sep-24 5:08 PM View: | Huber Martin H. Jr. President, CEO Director | Mersana Therapeutics, Inc. (MRSN) | 11-Sep-24 | Option Exercise | 166,750 | -- | -- | 100% 0 to 166.75K | |
| 17-Jan-24 5:16 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 3,431 | $2.71 | $9,298.01 | (20%) 17.48K to 14.05K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 4,381 | $2.71 | $11,872.50 | (14%) 31.78K to 27.4K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 3,357 | $2.71 | $9,097.47 | (16%) 21.32K to 17.97K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 10,409 | $2.71 | $28,208.40 | (5%) 209.74K to 199.33K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 29,399 | $2.71 | $79,671.30 | (6%) 467.06K to 437.66K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 5,025 | $2.71 | $13,617.80 | (18%) 28.35K to 23.33K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 9,327 | $2.71 | $25,276.20 | (15%) 63.84K to 54.51K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 38,958 | -- | -- | 9% 428.1K to 467.06K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 5,352 | -- | -- | 23% 23.0K to 28.35K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 10,208 | -- | -- | 19% 53.63K to 63.84K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 15,208 | -- | -- | 8% 194.53K to 209.74K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 6,250 | -- | -- | 13% 49.38K to 55.63K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 4,792 | -- | -- | 3% 189.74K to 194.53K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 2,500 | -- | -- | 9% 29.28K to 31.78K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 16,750 | -- | -- | 4% 411.35K to 428.1K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 1,458 | -- | -- | 7% 19.86K to 21.32K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 4,783 | -- | -- | 26% 18.22K to 23.0K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 9,375 | -- | -- | 5% 180.36K to 189.74K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 8,958 | -- | -- | 44% 20.33K to 29.28K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 31,250 | -- | -- | 8% 380.1K to 411.35K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 7,083 | -- | -- | 55% 12.78K to 19.86K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 2,645 | -- | -- | 17% 15.57K to 18.22K | |
| 17-Jan-24 5:16 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 8,750 | -- | -- | 100% 8.73K to 17.48K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 10,000 | -- | -- | 27% 37.38K to 47.38K | |
| 04-Jan-24 4:11 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 02-Jan-24 | Grant | 6,112 | -- | -- | 18% 33.07K to 39.18K | |
| 04-Jan-24 4:11 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 02-Jan-24 | Grant | 8,810 | -- | -- | 1% 589.48K to 598.29K | |
| 27-Oct-23 4:07 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 26-Oct-23 | Planned Option Sale | 1,912 | $1.13 | $2,160.56 | (18%) 10.64K to 8.73K | |
| 27-Oct-23 4:07 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 25-Oct-23 | Option Exercise | 6,250 | -- | -- | 142% 4.39K to 10.64K | |
| 04-Oct-23 4:30 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-23 | Grant | 11,011 | -- | -- | 50% 22.06K to 33.07K | |
| 04-Oct-23 4:26 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-23 | Grant | 15,873 | -- | -- | 3% 573.61K to 589.48K | |
| 13-Sep-23 4:02 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 11-Sep-23 | Grant | 16,643 | -- | -- | 5% 363.46K to 380.1K | |
| 18-Aug-23 4:01 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 17-Aug-23 | Planned Option Sale | 1,908 | $1.18 | $2,251.44 | (14%) 13.41K to 11.51K | |
| 18-Aug-23 4:01 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Aug-23 | Option Exercise | 6,250 | -- | -- | 87% 7.17K to 13.41K |
